Cardiovascular disease (CVD) accounts for approximately one-third of all global deaths, and acute coronary syndrome (ACS) is the most severe form of CVD. It is of notable importance to develop ACS strategies for reducing major adverse cardiac events (MACE) and preventing complications. In the Taiwan ACS Full Spectrum Registry, 1-year mortality among patients with ST-segment elevation myocardial infarction, non ST-segment elevation myocardial infarction and unstable angina was 6.1%, 10.1%, and 6.2%, respectively. ACS patients with diabetes had significantly worse outcomes in terms of all-cause death and MACE compared to those without diabetes. In-hospital bleeding or chronic kidney disease (CKD) was independently associated with MACE, and ACS patients with both bleeding and CKD had the worst outcome. Use of clopidogrel in conjunction with an invasive strategy could decrease mortality and improve outcomes in the CKD population. CHADS2 and CHA2DS2-VASc scores were useful predictors of subsequent MACE, and renal dysfunction could further improve the prognostic impact of the CHA2DS2-VASc score. For high-risk patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), percutaneous coronary intervention (PCI) within 24-72 hours from symptom onset was demonstrably the optimal time. Suboptimal secondary preventive therapy demonstrated a need for further improvement. The ACS Full Spectrum Registry provided an in-depth analysis of ACS management in Taiwan.
Keywords: Bleeding; CHA2DS2-VASc; Chronic kidney disease; Diabetes; NSTE-ACS; Taiwan Acute Coronary Syndrome Full Spectrum Registry.